What Are Chinese Pharma CEOs Ranting About? (Part 2 of 2)
This article was originally published in PharmAsia News
Top pharma executives get the chance to air their grievances during a once-a-year “meet the regulators” session in Beijing. In this second part of coverage of the meeting, China FDA director Wang Lifeng discusses marketing authorization holder pilots while CEOs including Betta’s Ding Lieming touch upon provincial tenders, orphan drugs and patent invalidity appeals.